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Abstract
During COVID-19, diagnostic serological tools and vaccines have been developed. To inform control activities in a post-
vaccine surveillance setting, we have developed an online “immuno-analytics” resource that combines epitope,
sequence, protein and SARS-CoV-2 mutation analysis. SARS-CoV-2 spike and nucleocapsid proteins are both vaccine
and serological diagnostic targets. Using the tool, the nucleocapsid protein appears to be a sub-optimal target for use
in serological platforms. Spike D614G (and nsp12 L314P) mutations were most frequent (> 86%), whilst spike A222V/
L18F have recently increased. Also, Orf3a proteins may be a suitable target for serology. The tool can accessed from:
http://genomics.lshtm.ac.uk/immuno (online); https://github.com/dan-ward-bio/COVID-immunoanalytics (source code).
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Background
COVID-19, the disease caused by the SARS-CoV-2 virus,
was first characterised in the city of Wuhan, Hubei, and
has now spread to 190 countries. With over 60 million
confirmed cases worldwide and more than 1.26 million
deaths, the COVID-19 pandemic has placed a high bur-
den on the world’s healthcare infrastructure and econ-
omies, with projected final costs of 28 trillion or 31% of
the global gross domestic product [1, 2]. The majority of
infections are either asymptomatic or result in mild flu-
like symptoms, with severe cases of viral pneumonia af-
fecting between 1.0% (≥ 20 years) and 18.4% (≥ 80 years)
of diagnosed patients [3]. Its variable infection outcome,
mode of transmission and incubation period together
have enhanced the ability of the pathogen to spread effi-
ciently worldwide. As a result, there has been an urgent
push for the development of diagnostics, therapeutics
and vaccines to aid control efforts.
Current front-line diagnostic strategies apply a quanti-
tative reverse transcription PCR (RT-qPCR) assay on pa-
tient nasopharyngeal swabs, using primer/probe sets
targeting the nsp10, RdRp, nsp14, envelope and nucleo-
capsid genes; tests endorsed by a number of agencies
and health systems [4, 5]. Patients hospitalised with se-
vere respiratory disease who are RT-qPCR negative may
be diagnosed radiographically (chest x-ray or compu-
terised tomography scan), but in limited resource or
high infection rate settings, these methods maybe un-
viable. Considering the inherent limitations in the sam-
ple collection process and transient viral load, RNA
detection-based diagnostics can vary in their sensitivity.
The demand for serological diagnostics is high, particu-
larly because these tests are capable of detecting SARS-
CoV-2 antibodies, which are biomarkers indicative of
current infection that remains present after viral clear-
ance [6]. These tools are essential to address crucial
sero-epidemiological questions, like understanding viral
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prevalence across a population, the percentage of asymp-
tomatic patients and longevity of antibody responses
post infection.
Numerous lateral flow rapid diagnostic tests (RDTs)
and enzyme-linked immunosorbent assays (ELISA) tests
have been developed, including an approved IgM/IgG
RDT which uses the nucleocapsid protein as a target for
the detection of seroconverted individuals [7]. Other as-
says use the spike protein as an antigen, with some using
the receptor-binding domain (RBD) as a target, a region
with a high level of diversity between alphacoronavirus
species [8]. Unlike RNA detection methods, these plat-
forms can identify convalescent patients, which further
informs outbreak control efforts.
Long-term control strategies will involve vaccine roll-
out. As of November 2020, there were more than 50
vaccines at development phase 1 or greater, with at least
10 vaccines in phase 3 [9, 10]. Vaccines at the forefront
include those based on a non-replicating adenovirus vec-
tor base (ChAdOx-nCoV-19 and Ad5-nCov), an LNP-
encapsulated mRNA (BNT162 and mRNA-1273), pro-
tein subunit (NVX-CoV2373) or inactivated virus
(BBIBP-CorV and CoronaVac) [11]. The discovery, de-
velopment and management of efficacious vaccines, as
well as sensitive and specific serological diagnostics, are
both dependant on the availability of up-to-date infor-
mation on viral evolution and immune-informatic ana-
lyses. The identification of variable or conserved regions
in the proteome of SARS-CoV-2 can inform the rational
selection of reverse-design targets in both vaccinology
and diagnostic fields, as well as indicate immunologically
relevant regions of interest for further studies to charac-
terise SARS-CoV-2 immune responses. Whilst the avail-
ability of biological data for SARS-CoV-2 in the public
domain has increased, insights are most likely to come




Here, we present an online integrated immuno-analytic
resource for the visualisation and extraction of SARS-
CoV-2 meta-analysis data [12]. This website was built
around an automated pipeline for the formation of a
whole genome sequence based variant database for
SARS-CoV-2 isolates worldwide (as of November 2020,
n = 150,090). We have integrated this dataset with a suite
of B cell epitope prediction platform meta analyses,
HLA-I and HLA-II peptide prediction, an ‘epitope map-
ping’ analysis of available experimental in vitro con-
firmed epitope data from the Immune Epitope Database
(IEDB) [13] and a protein orthologue sequence analysis
of six relevant coronavirus species (SARS, MERS, OC43,
HKU1, NL63 and 229E), with all data updated and
annotated regularly with information from the UniProt
database. Additional functionality enables users to visu-
alise external analytical datasets presented in the litera-
ture (e.g. [14]). Moreover, we have added functionally to
spatio-temporally track non-synonymous mutations of
interest through the dataset, allowing up-to-date surveil-
lance of mutations that may be of immunological rele-
vance. With this resource, users can browse the
annotated SARS-CoV-2 proteome and extract meta data
to inform further research and analyses.
Whole genome sequence data analysis
SARS-CoV-2 nucleotide sequences were downloaded
from NCBI (https://www.ncbi.nlm.nih.gov) and GISAID
(https://www.gisaid.org). As part of an automated in-
house pipeline, sequences were aligned using MAFFT
software (v7.2) [15] and trimmed to the beginning of the
first reading frame (orf1ab-nsp1). Sequences with > 20%
missing were excluded from the dataset. Using data
available from the NCBI COVID-19 resource, a modified
annotation (GFF) file was generated and open reading
frames (ORFs) for each respective viral protein were ex-
tracted (taking in to account ribosomal slippage) using
the bedtools ‘getfasta’ function [16]. Each ORF was
translated using EMBOSS transeq software [17], and the
variants for each protein sequence were identified using
an in-house script [18]. As a part of our analysis pipe-
line, we generated consensus sequences for each SARS-
CoV-2 protein from the nucleotide database using the
EMBOSS Cons CLI tool [17]. These canonical sequences
were used as a reference for prediction, specificity and
epitope mapping analyses.
B cell epitope prediction meta-analysis
Six epitope prediction software platforms were chosen
for this analysis (Bepipred [19], AAPpred [20] DRREP
[21], ABCpred [22], LBtope [23] and BCEpreds [24]).
For each tool, we used the settings and quality cut-offs
as recommended by their respective authors. The scores
across the predictive platforms were then normalised
(minimum-maximum scaled) to ensure that no single
tool skewed the aggregate ‘consensus’ score, and com-
bined to provide a single consensus B cell epitope pre-
diction score. Within the ‘raw data table’ (accessed from
the tool’s landing page), users can dissect each score de-
pending on their preference of methodology.
HLA-I and HLA-II peptide prediction
We have incorporated an HLA-I peptide prediction ana-
lysis within the tool to aid in the scrutiny and develop-
ment of vaccine candidates. CD8+ effector immunity has
been reported to play a central role in the response to
SARS-CoV infection, as well as infection mediated im-
munopathology [25–27]. We used a database of 2915
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HLA-A, HLA-B and HLA-C alleles to make HLA-I pep-
tide binding predictions using the netMHCpan server
(v4.1) [28], with peptide lengths of 8 to 14 amino acids
across the entire SARS-CoV-2 proteome. We chose to
use the netMHCpan server for our HLA-I peptide pre-
diction analysis, due to its high overall performance and
its extensive HLA-I allele database [28]. We ran predic-
tions for a total of 2915 alleles (HLA-A 886, HLA-B
1412 and HLA-C 617) across all peptide lengths (8–14
amino acids). The analysis generated 1.1 billion candi-
dates. After quality control, we selected a total of 736,
073 peptides based on strong binding affinity across the
allele database. We selected strong binding affinity pep-
tides based on the tools internal binding scoring metrics.
Only ‘strong binding’ alleles were selected for further
analysis. For each position with a ligand with high bind-
ing affinity, we analysed the percentage representation of
the respective HLA-I type across the allele database. For
predicting HLA-II peptides we used the MARIA online
tool [29]. We pre-processed the SARS-CoV-2 canonical
protein sequences using a 15 amino acid sliding window.
Predictions were made for all available HLA-II alleles. A
95% cut off was chosen for a positive HLA-II presenta-
tion. All data for each 15-mer is displayed on the tool.
Epitope mapping
B cell epitopes for coronavirus species were sourced
from the Immune Epitope Database (IEDB) resource
(https://www.iedb.org, updated: October 2020) [13].
Using BLASTp [30], we mapped short amino acid epi-
tope sequences onto the canonical sequence of SARS-
CoV-2 proteins. A BLASTp bitscore of 25 with a mini-
mum length of 8 residues was selected as a quality cut-
off for mapped epitopes. The frequency of mapped epi-
topes was logged for each position in the protein and
parsed for graphical representation.
Coronavirus homology analysis
Reference proteomes for SARS, MERS, OC43, 229E,
HKU1 and NL63 α and β coronavirus (-CoV) species
were sourced from UniProt database. These sequences
were processed into 10-mers using the pyfasta platform
and mapped on to the canonical sequences of SARS-
CoV-2 proteins using the aforementioned ‘epitope map-
ping’ process. The k-mer mapping technique applied a
matching threshold of at least 10 residues in orthologous
viral proteins, which is of sufficient length to cover
HLA-bound peptides and/or whole or part of a B cell
epitope, something that is challenging using only pair-
wise multiple sequence alignments. Homologous peptide
sequences with a BLAST bitscore indicating 10 or more
residues mapped to the target sequence were recorded
and parsed for display on the graph.
Online SARS-CoV-2 “Immuno-analytics” resource and
analysis software
We developed an online immuno-analytics resource with
an interactive plot that integrates up-to-date SARS-CoV-2
genetic variation analysis, T and B cell epitope prediction
and mapping, human coronavirus homology mapping, lit-
erature meta-analysis and an accessible database for
extracting data for further study. This tool is available on-
line from http://genomics.lshtm.ac.uk/immuno. The
source code for the website and up-to-date raw data files
are available at https://github.com/dan-ward-bio/COVID-
immunoanalytics [18] (see Additional file 1: Fig. S1 for
screenshots). The BioCircos.js library [12] was used to
generate the interactive plot and Datatables.net libraries
for the table. The underlying web-tool software and in-
house pipelines for data analysis are available at https://
github.com/dan-ward-bio/COVID-immunoanalytics [18].
Metadata consisting of collection date and source
(geographical) location for each GISAID sequence are
analysed. Temporal and geographic data on individual
mutations can be found on the ‘Mutation Tracker’ page,
accessed via the tool’s home page. For the spatio-
temporal mutation plots, we partitioned the whole gen-
ome sequencing dataset by week and continent and plot-
ted non-synonymous allele frequencies using Google
Charts JavaScript libraries. To improve sustainability of
the tool, all functions and data of the website are gener-
ated and updated using automated data scripts devel-
oped in-house.
Utility and discussion
To demonstrate the functionality of the immuno-
analytics tool, we present an analysis of the SARS-CoV-2
spike, nucleocapsid and orf3a proteins, which are vac-
cine and serological targets. Analysis of 150,090 SARS-
CoV-2 sequences identified 911,324 non-synonymous
mutations across 16,951 sites in protein-coding regions;
0.71% of these mutations are singleton events and 0.03%
(46) of these mutations have a frequency above 1%, oc-
curring in > 1500 samples. The most frequent mutations
were the spike protein D614G (87.3%) and nsp12 L314P
(87.5%), which were common across all the geographical
regions (all > 86%) (Table 1), in keeping with their deep
ancestral nature in the SARS-CoV-2 phylogenetic tree
[24]. In particular, nsp12 L314P has been used to geno-
type the putative S and L strains of SARS-CoV-2, which
have now been clustered into further groups [31]. Spike
D614G lies 73 residues downstream from the spike
RBD, a region of interest as it is a primary target of pro-
tective humoral responses and bears immunodominant
epitopes that play a possible role in antibody dependant
enhancement [32–35]. We have observed a strong cor-
relation between the spatiotemporal accumulation of
both spike D614G and nsp12 L314P (Fig. 1, Table 1),
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due to either a common origin and subsequently linked
accumulation by a founder effect or a more complex
biological interaction, including positive selection driven
in part by increased transmissibility, as suggested by a
recent study [36]. Specifically, the spike D614G and
nsp12 N314L both appear to have a near-identical fre-
quency with a consistent increase across all geographic
regions (negating weeks with poor data collection). In
contrast, the frequency of orf3a Q57H appears to fluctu-
ate, increasing and decreasing significantly from the time
it was first observed in February 2020 (week 8) to No-
vember 2020, week 43) (Fig. 1; Table 1). Using the
immuno-analytical tool, spike A222V, S477N and L18F
variants were observed to have increased significantly in
frequency between May and November 2020 (weeks 23–
40). Spike mutations A222V and L18F appear to have
become entrenched in Europe reaching a total frequency
of 70.6% and 31.6%, respectively (Additional file 1: Table
S1, Additional file 1: Fig. S2). Moreover, A222V appears
to be increasing in Asia and Oceania from week 41, and
S477N has increased to > 95% frequency across Oceania
(N = 8321) with a peak of 9.3% in Europe (Additional file
1: Table S1, Additional file 1: Fig. S2), consistent with a
recent report [37].
The proximity of the D614G mutation to one of the
functional domains of the spike protein has raised con-
cerns, but whether it confers any gain in pathogenicity,
transmissibility or immune evasion is still unclear [32].
Other high frequency mutations occur on the nucleo-
capsid gene (R203K, 38.8.0%; G204R 38.4%; across all
geographical regions > 31%; Table 1), which has been
the target antigen for several serological RDTs currently
in use or in production. Both of these mutations share a
near-identical spatio-temporal profile. We have identi-
fied 363 non-synonymous variant sites across the nu-
cleocapsid gene with mutations occurring 173,955 times
in this dataset. Using the SARS-CoV-2 immuno-
analytics platform, we further queried these polymorphic
regions for immunological relevance. The 20 residues
surrounding the spike mutation D614G (S604-624)























S 614 D V:G:S:N 1:131490:2:
10
0.877 0.975 0.940 0.866 0.890 0.866 0.868 0.883
nsp12 314 N H:F:L:S 2:114:
131053:1
0.876 0.973 0.938 0.863 0.887 0.876 0.865 0.881




0.388 0.426 0.394 0.374 0.316 0.393 0.440 0.380




0.385 0.424 0.393 0.373 0.312 0.392 0.439 0.379




0.234 0.267 0.227 0.236 0.210 0.193 0.199 0.248
nsp2 85 T V:I 1:25913 0.173 0.195 0.156 0.180 0.160 0.090 0.153 0.180
nsp6 37 L F 11,992 0.080 0.087 0.112 0.079 0.061 0.082 0.073 0.079
nsp2 120 I V:F:M 7:11996:1 0.080 0.094 0.061 0.082 0.059 0.054 0.059 0.083




0.079 0.099 0.148 0.057 0.177 0.135 0.026 0.085
orf10 30 V A:I:L 2:2:11619 0.078 0.097 0.146 0.056 0.176 0.132 0.025 0.084
N 220 A V:T 11,555:5 0.077 0.097 0.146 0.056 0.176 0.131 0.025 0.083




0.067 0.077 0.044 0.070 0.048 0.045 0.043 0.068
N 194 S A:L:P:T 30:6441:2:1 0.043 0.052 0.043 0.035 0.031 0.053 0.038 0.049
orf8 84 L F:C:S:V 1:1:6338:1 0.042 0.046 0.053 0.043 0.049 0.040 0.048 0.042
orf8 24 S L 6151 0.041 0.053 0.033 0.036 0.034 0.009 0.022 0.048
S 18 L F:I 5888:1 0.040 0.048 0.071 0.030 0.106 0.059 0.017 0.041
nsp5 15 G S:D 5433:5 0.036 0.039 0.035 0.036 0.022 0.038 0.044 0.036
orf3a 251 G V:S:D:C 5252:31:4:6 0.035 0.035 0.063 0.037 0.031 0.040 0.034 0.030
nsp13 541 Y C 2606 0.017 0.019 0.032 0.017 0.018 0.021 0.019 0.017
nsp13 504 P L:H:S 2535:1:111 0.017 0.020 0.032 0.017 0.018 0.022 0.021 0.017
Pos. position, Freq. frequency, NAm North America, SAm South America, AFR Africa, OCE Oceania, REF reference, ALT alternative, *S spike, M membrane, N
nucleocapsid, ** included in Europe
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(Fig. 2) have a high epitope prediction meta-score (34%
increase on the global median) with 204 IEDB epitope
positions mapping to the surrounding residues, suggest-
ing that this region is of high interest and may elicit a
strong immune response. On top of the high level of
SARS-CoV sequence homology reported, we have identi-
fied multiple clusters in the S2 domain of the spike
protein, with homology to MERS, OC43, 229E, HKU1
and NL63 human coronaviruses, which may elicit a
cross-reactive immune response in immune sera. Hu-
man coronavirus sequence homology is greatly reduced
in the S1 domain, with only two small 10-residue
pockets of OC43 and HKU1 identity (see Fig. 2). We ob-





Fig. 1 a–c High frequency non-synonymous spike D614G, NSP12 N314L and orf3A Q57H mutations found in SARS-CoV-2 plotted weekly by continent. This
functionality is available on the website. Users can select any mutation from the main plot and visualise it temporally and geographically. UK sequences are not
included in Europe due to high frequency. d A stacked bar chart representing total sequences published by each continent by week. This chart is included to
assist users understand how allele frequencies may be affected by poor sampling. (see http://genomics.lshtm.ac.uk/immuno/mutation_tracker)
Ward et al. Genome Medicine            (2021) 13:4 Page 5 of 12
score within the receptor-binding motif (AA437-508), a
region implicated in the direct ACE2 (angiotensin-con-
verting enzyme 2) interaction. HLA-II peptide binding
prediction (see Fig. 3) yielded several epitopes within the
receptor-binding domain with high HLA-II ligand affin-
ity, as well as strong B cell epitope prediction scores
(28% above the global median). Metadata obtained from
the UniProt database reveals 3 clusters of glycosylated
residues across the spike protein, a characteristic
highlighted by this tool that should be considered
when choosing expression systems for producing pro-
tein/peptides based on these regions.
For two high-frequency non-synonymous nucleocapsid
protein mutations (R203K and G204R; co-fixed), all but
three of the 30 (N173-234) flanking residues have non-
synonymous variants, with 5 sites reporting an
Fig. 2 Linearised extracts from the SARS-CoV-2 immuno-analytics resource database; spike, nucleocapsid and orf3a proteins. Non-synonymous
mutations, B cell epitope prediction meta-score, IEDB epitope mapping and sequence identity analyses were plotted (see key). Left axis denotes
the scale for epitope prediction and IEDB mapping. Right axis denotes the relative allele frequency found in the genome dataset; AA, amino acid
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Fig. 3 Mapping of HLA-I A and B epitopes to the spike, nucleocapsid and orf3a protein sequences. Epitopes were inferred using NetMHCpan 4.1.
Only strong binding epitopes were selected for analysis, based on the tool’s internal classification system. A representative set of HLA-I alleles
were used as described in Grifoni et al. [14]. Binding affinity is based on predicted IC50 values (nM) (a lower concentration equates to a stronger
affinity). Shaded region (denoted by A) indicates the spike receptor-binding domain (RBD)
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alternative allele frequency greater than 1% (A220V,
S194L, S197L, M234I and P199L:S). The average epitope
meta-score for these variant sites is 30% above the global
median prediction score, with the two aforementioned
high frequency mutant residues scoring 35% above the
global median epitope predictive score. The sequence
homology analysis of the nucleocapsid protein revealed a
high level of shared identity between SARS-CoV (90%)
and MERS-CoV (45%) on a per-residue basis. The nu-
cleocapsid protein analysis revealed two clusters of
shared human coronavirus orthologue identity (Fig. 2),
one of which was found to cross the aforementioned
N173-234 region with identity to HKU1, NL63, MERS
and SARS detected. Moreover, these clusters were found
to have an increased IEDB epitope mapping frequency,
high polymorphism frequency and B cell epitope meta-
scores (23% above the global median), indicative of po-
tential B cell immunogenicity. We focused on two nu-
cleocapsid protein specific regions of interest (amino
acids 102 to 137 and 167 to 206; Fig. 2). Within the first
35-residue region (amino acids 102 to 137), we have de-
tected NL63, SARS, OC43, 229E, MERS and HKU1 hu-
man coronavirus homology. Further, we observed an
increase in mapped IEDB epitopes, including mapped
linear peptidic B and T cell epitopes from avian gamma-
coronavirus, murine betacoronavirus, feline and canine
alphacoronavirus-1 providing in vitro confirmation that
peptides within this region may indeed serve as im-
munogenic cross-reactive epitopes. The second region
(amino acids 167 to 206) contains the R203K and
G204R mutations along with a cluster of high frequency
variants. We detected homology with HKU1, NL63 and
MERS human coronavirus species along with a high fre-
quency of SARS and murine coronavirus mapped IEDB
epitopes, with a 34% increase on the median B-cell epi-
tope prediction meta-score.
Previous studies of adaptive cellular effector immune
responses to SARS-CoV infection have emphasised the
importance of spike peptide presentation in the progres-
sion and severity of disease; regions of particular interest
include the following: S436–443, S525–532, S366–374,
S978,and S1202 [25, 26, 38]. We analysed these regions
for their performance as HLA-I ligands in silico and
found that all of the regions of interest had a high bind-
ing affinity scores associated with that position. More-
over, these peptides were widely represented in the
predictions made across the 2915 HLA-A, -B and -C al-
leles used in this analysis. Taking into account all avail-
able HLA-A, B and C alleles, we found the spike
peptides had an average allele coverage of 21%, 18% and
34% respectively. We performed an analysis to include
12 alleles with the highest frequency observed across the
human population, as reported recently [14]. We found
that peptides in the S366-374 and S1202 regions had
high representation across the subset of 12 high fre-
quency HLA-I alleles (Fig. 3). These findings imply that
the peptides as HLA-I ligands may have a putative role
in initiating a protective cellular response in SARS-CoV-
2 infections across a significant proportion of the HLA-I
population worldwide. We have identified another re-
gion of interest that scores highly in the HLA-I peptide
binding analysis. The S690-700 region has a high fre-
quency of peptides with a high binding affinity with
significant representation across all HLA-I alleles (HLA-
A 40%, -B 23%, -C 60%). Furthermore, we have observed
no mutations present in this region based on our SARS-
CoV-2 variant analysis, implying this peptide appears to
remain conserved making it a prime candidate for fur-
ther study. The spike D614G mutation does not appear
to have significantly elevated HLA-I epitope prediction
scores (Fig. 3), a finding supported by recent work [39].
The biological importance of spike D614G, particularly
its immunological relevance and impact on transmission
and disease, are still unclear [40, 41].
Protein 3a (orf3a) has been reported to play a role in
host immune modulation by decreasing interferon
alpha-receptor expression in SARS-CoV-infected cells
and activating the NLRP3 inflammasome [42, 43], a re-
sponse that may boost inflammation mediated COVID-
19 pathology. Orf3a has been a target for SARS-CoV
vaccinology studies, with reports of it eliciting potentially
protective responses in both protein and DNA forms
[27, 44]. These immunogenic properties appear con-
served in the SARS-CoV-2 orthologue, with consistently
strong antibody responses reported in COVID-19 pa-
tients [45]. Looking across the SARS-CoV-2 proteome,
of the 50 residues with the highest B cell epitope predic-
tion meta-score, orf3a occupies 16%, despite only consti-
tuting 2.5% of the total SARS-CoV-2 protein sequence.
Moreover, there are numerous high affinity HLA-II epi-
topes, which may serve to elicit strong antibody re-
sponses. Although protein orf3a shares a high level of
identity with its SARS-CoV orthologue, we detected no
amino acid sequence homology with OC43, NL63,
HKU1 and 229E human coronavirus species or any non-
SARS-CoV IEDB epitopes.
Our analysis of the 150,090 SAR-CoV-2 whole genome
sequences detected 267 variant sites within orf3a, with
non-synonymous mutations occurring 68,473 times. A
minority of these variant sites are singletons (8.2%) and
five (1.8%) have a frequency higher than 1% (> 1500 iso-
lates), with a non-synonymous mutation density 40%
lower than that of the nucleocapsid. The variant sites
identified in the orf3a gene have a mean epitope predict-
ive meta-score of 2.3, which is equal to the median glo-
bal score, indicating that these sites may not form a part
of a B cell epitope. Comparing the predictive meta-
scores of the nucleocapsid protein variant sites, we
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observed an increase of 26% over the global median, in-
dicating that nucleocapsid protein non-synonymous mu-
tations may impact epitope variability more than those
found in orf3a. CD8+ effector responses to protein 3a
have been characterised in SARS-CoV patients and ap-
pear to play a significant role in immunity [26, 46, 47].
Notably, alongside two within the spike protein, a pep-
tide in orf3a (orf3a 36-50) has been found to form a part
of the public (conserved) T cell epitope repertoire across
SARS-CoV patients [47]. This region scores highly in
the HLA-II predictions with numerous HLA-A and
HLA-B high affinity peptides covered (HLA-A 19%, -B
41%, -C 48%) and is relatively conserved with few low
frequency non-synonymous mutations (maximum mu-
tant allele frequency of 0.00219 (65 times)). We have
identified one further region in orf3a (101-121) that
scores highly with HLA-I epitope prediction across fre-
quent HLA-I alleles (Fig. 3) and therefore may be of
interest to those studying HLA-I ligands. For HLA-I pre-
diction, we observed that orf3a performs significantly
better than the nucleocapsid. Despite the nucleocapsid
protein sequence being 52% larger than that of orf3a,
there are 34% more high affinity HLA-I epitopes across
our subset of 12 frequent HLA-I alleles (Fig. 3), which
may indicate that orf3a has a more immunodominant
role in cellular responses following intracellular process-
ing when compared to the nucleocapsid protein.
Overall, we have developed an immuno-analytical tool
that combines in silico prediction data with in vitro epi-
tope mapping, SARS-CoV-2 genome variation and a k-
mer-based human coronavirus sequence homology with
curated functional annotation data. Furthermore, we
have added functionality enabling users to track muta-
tions geographically across time. An additional frame-
work exists to annotate positions with relevant findings
from the literature to further guide users’ research. The
integration and co-visualisation of these data support
the rational selection of diagnostics, vaccine targets with
reverse immunology, and highlight regions for further
immunological studies. We demonstrate the utility of
the tool through the analysis of three proteins and their
mutant positions, which are of relevance to current
SARS-CoV-2 research.
Understanding the magnitude of transmission and pat-
terns of infection will lead to insights for post-isolation
strategies. The rapid emergence of the SARS-CoV-2
virus called for an expediated process to deploy sero-
logical RDTs for the detection of SARS-CoV-2 IgG/IgM
antibody responses. There were reports early in the out-
break of lateral flow SARS-CoV-2 Ig RDTs not reaching
sufficiently high levels of sensitivity and specificity [43].
While many assays use the spike protein as its sole anti-
gen for antibody detection, others employ a combination
of the spike and nucleocapsid proteins; other assays have
been based solely on the nucleocapsid protein [7]. Our
analyses suggest that, in its native form, the nucleocapsid
protein may prove a sub-optimal target for use in sero-
logical diagnostic platforms. It possesses the greatest
number of residues across all SARS-CoV-2 genes with
high-frequency non-synonymous mutations, the majority
of which have a high predictive epitope and IEDB epi-
tope mapping scores when compared to variant posi-
tions of other genes. This implies that there may be an
inherent variability in dominant antibody responses to
different nucleocapsid protein isoforms, which may work
to confound testing. We have located three regions of
homology with other highly prevalent human corona-
virus species, which could serve as non-specific SARS-
CoV-2 epitopes if used in serological assays. Moreover,
we have emphasised the high level of SARS-CoV identity
across the SARS-CoV-2 proteome (except in orf8 and
orf10), which may have implications for diagnostic de-
ployment in countries that have had outbreaks involving
SARS-CoV.
The spike protein has remained a focus of both vac-
cine and diagnostic research. Its functional role in viral
entry imparts this antigen with immunodominant and
neutralising antibody responses [29, 44]. This role is re-
inforced in our analyses, with several clusters of high
epitope meta-scores in functional regions and high IEDB
epitope mapping counts. The S1 domain has been the
focus of a number of studies looking for specific anti-
gens, not least because of its apparent lack of sequence
homology with other human coronavirus species when
compared to regions in the S2 domain, as well as its
strong functional and immunogenic role in SARS-CoV-2
infection [7, 40, 44, 45]. However, as vaccination pro-
grammes begin, most of which will target the spike pro-
tein, it will become challenging to differentiate
vaccination responses from those elicited by SARS-CoV-
2 infection. Therefore, alternative viable targets for sero-
logical screening may be needed.
The broad nature of the analyses performed by our
tool may assist in the understanding of vaccine targets,
during both design and testing phases. The prediction of
HLA-I ligands is relevant not only to the study of struc-
tural viral targets, but the full range of potentially im-
munologically relevant endogenous proteins that may be
presented following intracellular processing, some of
which may have less coverage in the literature. Our
broad approach to HLA-I ligand prediction ensures that
researchers can assess the applicability of in silico in-
formed vaccine targets across different populations. Fur-
ther, ensuring that targets are both specific and devoid
of polymorphism is essential to ensuring the longevity of
vaccine responses and diagnostic capabilities, the ana-
lysis of which is achieved easily with our tool. The
humoral and cellular immune responses as well as the
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affects of human coronavirus protein homology to
SARS-CoV-2 proteins have yet to be fully characterised.
With the significant levels of amino-acid sequence iden-
tity between SARS-CoV-2 and other human coronavirus
species detected in our analysis, researchers should be
wary of the potentially deleterious effects of both non-
specific humoral and cellular responses in enhancing in-
fection; a phenomenon observed in a number of other
viral pathology models. While the tracing and monitor-
ing of non-synonymous mutations and their spatio-
temporal analysis provides an initial indication of their
importance, potentially the impact of evolutionary pres-
sures on loci of interest, further analyses on signals of
selection may provide additional insights. Computer in-
tensive genome-wide analyses of positive selection are
becoming available (e g. http://covid19.datamonkey.org/)
and may be used to complement insights from our
immuno-analytical tool.
In summary, using the SARS-CoV-2 immuno-analytics
platform, we were able to identify shortcomings in
current targets for diagnostics and suggest orf3a as an-
other target for further study. This protein has proven
in vitro immunogenicity in COVID-19 patients, and
promising functional aspects were supported by our in-
tegrated data analysis using the tool. The database
underpinning the online tool is updated automatically
using data parsing scripts that require minimal human
curation. The monitoring of the temporal changes in the
frequencies of mutations or their presence in multiple
clades in a SARS-CoV-2 phylogenetic tree could provide
insights for infection control, including post-vaccine
introduction. Importantly, our open-access platform and
tool enables the acquisition of all of the aforementioned
data associated with the SARS-CoV-2 proteome, assist-
ing further important research on COVID-19 control
tools.
Conclusions
The SARS-CoV-2 immuno-analytics platform enables the
visualisation of multidimensional data to inform target se-
lection in vaccine, diagnostic and immunological research.
By integrating genomic and whole-proteome analyses with
in silico epitope predictions, we have highlighted import-
ant advantages and shortcomings of two proteins at the
foci of COVID-19 research (spike and nucleocapsid),
while suggesting another candidate for further study
(orf3a). Both spike and nucleocapsid proteins have regions
of high identity shared with other endemic human cor-
onavirus species. Moreover, several high frequency muta-
tions found in our dataset lie within putative T and B cell
epitopes, something that should be taken into consider-
ation when designing vaccines and diagnostics. Further,
our work is likely to become more important as the roll-
out of vaccines will introduce new selection pressures that
will need to be monitored for escape variations. The
immuno-analytics tool can be accessed online (http://
genomics.lshtm.ac.uk/immuno), and the source code is
available on GitHub (https://github.com/dan-ward-bio/
COVID-immunoanalytics) [18].
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